Phase 2 Mesothelioma Trial, Recruiting NCT06543069 Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Condition: Mesothelioma
Back to Mesothelioma

Phase 2 Mesothelioma Trial, Recruiting

NCT06543069
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You fully understand the study and are willing to sign a consent form agreeing to take part
  • You are 18 years of age or older
  • You have been confirmed by a lab test (tissue or cell sample) to have peritoneal mesothelioma (a cancer affecting the lining of the abdomen)
  • You are generally able to care for yourself and are up and about for most of the day (a standard doctor's rating of your daily functioning, scored 0 or 1)
  • Your doctors expect you to live for at least 3 more months
  • Your blood, liver, and kidney test results meet certain healthy levels (no blood transfusions or certain growth-boosting injections allowed in the 14 days before joining)
  • If you are a woman who could become pregnant, you must have a negative pregnancy test within 7 days before joining and agree to use reliable contraception during the trial and for 8 weeks after the last dose; if you are a man, you must either have had a sterilisation procedure or agree to use reliable contraception during the trial and for 8 weeks after the last dose
  • You have not taken part in any other clinical trial in the 4 weeks before joining, and will not do so during this study

Who may not be able to join:

  • You are unable or unwilling to follow the study rules and schedule
  • You have received a live vaccine within 4 weeks before joining, or are expected to need one during the study
  • You have had another type of cancer in the past 5 years, unless it was a fully cured skin cancer (certain types), a specific type of thyroid cancer, or early-stage cervical cancer that has been treated
  • You currently have, or have recently had (within 4 weeks), an active autoimmune disease (a condition where the immune system attacks the body)
  • You have previously received a bone marrow or organ transplant from another person
  • You have had a serious heart condition such as unstable chest pain or a heart attack within the past 6 months
  • You are allergic to the study drugs or any of their ingredients
  • Your blood clotting test results are above certain levels (confirm with trial site)
  • You have significant abnormalities in your blood salt/mineral levels, as judged by the doctor
  • You have uncontrolled high blood pressure before joining (top number 140 or higher and/or bottom number 90 or higher)
  • You have had significant bleeding episodes, coughing up blood, or a blood clot, stroke, or mini-stroke within the past 3 to 12 months (timeframes vary by event — confirm with trial site)
  • You have significant heart problems, including a recent heart attack, severe chest pain, recent bypass surgery, moderate-to-severe heart failure, certain irregular heart rhythms needing medication, or a weakened heart pump (confirm with trial site)
  • You have a serious active infection that is not under control
  • You are known to have HIV, or you have active hepatitis B or C infection confirmed by specific blood tests
  • You have any other serious illness, abnormal test results, or health condition that the doctor believes makes this trial unsuitable or risky for you
  • Your urine test shows a high level of protein, also confirmed by a 24-hour urine collection test
  • You need long-term treatment with immune-suppressing drugs or higher-dose steroid medications
  • The trial doctor has determined for any other reason that this trial is not appropriate for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yongkun Sun, Doctor, Cancer Institute and Hospital, Chinese Academy of Medical SciencesCancer

Phone: 13141276041

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Registry
ClinicalTrials.gov
Start date
31 January 2024
Est. completion
31 January 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-Free Survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov